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Background: A prognostic model was developed and validated using cancer registry data. This underpins
an online decision support tool, informing primary treatment choice for women aged 70 years or older
with hormone receptor-positive early breast cancer.
Methods: Data from women diagnosed between 2002 and 2010 in the English Northern and Yorkshire
and West Midlands regions were used to develop the model. Primary treatment options of surgery with
adjuvant endocrine therapy or primary endocrine therapy were compared. Models predicting the hazard
of breast cancer-specific mortality and hazard of other-cause mortality were combined to derive survival
probabilities. The model was validated externally using data from the Eastern Cancer Registration and
Information Centre.
Results: The model was developed using data from 23 842 women, and validated externally on a data
set from 14 526 patients. The overall model calibration was good. At 2 and 5 years, predicted mortality
from breast cancer and other causes differed from the observed rate by less than 1 per cent. At 5 years,
there were slight overpredictions in breast cancer mortality (2629 predicted versus 2556 observed deaths;
P = 0⋅142) and mortality from all causes (6399 versus 6320 respectively; P =0⋅583). The discrepancy varied
between subgroups. Model discrimination was 0⋅75 or above for all mortality measures.
Conclusion: A prognostic model for older women with oestrogen receptor-positive early breast cancer
was developed and validated in the present study. This forms a basis for an online decision support tool
(https://agegap.shef .ac.uk/).
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Introduction
Breast cancer is the most common cancer to affect women,
with 54 896 patients diagnosed in the UK in 20161. Around
one-third occur in women aged over 70 years. The stan-
dard of care for early breast cancer is surgical removal of
the primary cancer, axillary surgery, and adjuvant therapies
that may include chemotherapy, antihuman epidermal
growth factor receptor (HER2) therapy, bisphosphonates,
antioestrogens and radiotherapy. However, age-related
practice varies widely; older women are less likely to
receive adjuvant therapy than their younger counterparts2.
The National Institute for Health and Care Excellence3
recommends that women with early breast cancer, irre-
spective of age, are treated with surgery and systemic
therapy rather than endocrine therapy alone, unless sig-
nificant co-morbidity precludes surgery. However, up
to 40 per cent of older women with oestrogen receptor
(ER)-positive cancer in the UK have historically received
primary endocrine therapy.
Treatment with primary endocrine therapy is justified
in some instances. It was shown to be effective in sev-
eral trials in the 1980s, with no survival disadvantage
relative to surgery, although rates of local control were
suboptimal4. For some older women, surgery is associated
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Table 1 Patient characteristics used as co-variables in the two components of the prognostic model
Description Values In BCM model In OCM model
Treatment Primary treatment Surgery or primary endocrine therapy ✓
Age Age at diagnosis Age above 70 years ✓ ✓
Co-morbidity CCI minus age component 0, 1, 2, ≥3 ✓ ✓
Frailty ADL-related functional status 1, 2, 3, 4, 5 ✓
Grade Tumour grade I, II, III ✓
Nodal status Positive nodes present Yes, no ✓
Size Tumour size Size in mm ✓
Detection Detection method Screened or symptomatic ✓
Deprivation Average deprivation of patient postcode Low (1), medium (2–4), high (5) ✓
BCM, breast cancer mortality; OCM, other-cause mortality; CCI, Charlson Co-morbidity Index; ADL, activities of daily living.
with significant risks5 and others may prefer minimal
treatment6. Tang and colleagues5 reported unacceptable
rates of morbidity and mortality in surgically treated US
nursing home residents. Older and less fit women are
more likely to die from competing risks and may experi-
ence a significant decline in quality of life after surgery.
Selecting the best treatment for an individual woman
is complex and currently no tools exist to support the
decision.
Models to inform clinician and patient decisions about
adjuvant therapy after surgery already exist. They are based
on clinical prognosticators for recurrence risk and breast
cancer death. These include the Nottingham Prognostic
Index7, PREDICT8, Adjuvant! Online9, OPTIONS and
CancerMaths10. PREDICT is widely used in the UK, and
is based on clinicopathological factors including tumour
size, tumour grade, lymph node status, ER status, HER2
status and mode of detection. These models, however,
consider the impact of adjuvant treatment after surgery
rather than the initial decision regarding surgery itself.
They might give an estimate of the expected outcome for
an older woman having surgery, but not on the alterna-
tive of primary endocrine therapy. There is also evidence
that PREDICT may be less accurate in 10-year outcome
prediction in women aged over 75 years11. Existing prog-
nostic models do not explicitly consider age-related fac-
tors such as co-morbidities and frailty. Co-morbidity is
a strong predictor of competing mortality12 and should
be included when modelling an elderly population. Vari-
ations in functional and cognitive status and physiological
reserves in older populations should also be considered12.
In addition, deprivation level is usually linked to a higher
burden of co-morbidity and frailty, and possibly also to
undertreatment.
The aim of this study was to develop and validate
a new prognostic model to inform the primary treat-
ment choice (surgery or primary endocrine therapy) for
women aged at least 70 years with ER-positive early breast
cancer.
Methods
A prognostic model was developed comprising two sub-
models: breast cancer mortality and other-cause mortality.
Model parameters (Table 1) were selected based on liter-
ature review, exploratory investigation and expert advice.
The hazard of breast cancer mortality was modelled as
a function of patient age, co-morbidity score (Charlson
Co-morbidity Index (CCI) without the age component)
and deprivation level; tumour detection pathway; tumour
diameter, grade and nodal status; and treatment choice.
Registry data do not contain any information about con-
comitant co-morbidities and data on these were derived
from linked Hospital Episode Statistics (HES) data col-
lected during inpatient spells for patients with cancer. The
hazard of other-cause mortality was modelled as a function
of patient age, co-morbidity score and frailty. The subse-
quent model development procedure, including technical
details of how these co-variables were incorporated into the
model, is detailed in Appendix S1 (supporting information).
The resulting breast cancer mortality model was a
Royston–Parmar (RP) restricted cubic spline model with
eight co-variables. RP models allow relaxation of the
proportional hazards assumption associated with well
known Cox models13 and, being parametric, facilitate
extrapolation of survival predictions as required for prog-
nostic modelling. During the model building process,
evidence was found for non-proportional hazards for
some co-variables (Table 1). Interaction terms were also
found to be statistically significant between treatment and
three other co-variables: tumour grade, size and nodal
status. The coefficients of the breast cancer submodel
were estimated using the flexsurv library in the open
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Table 2 Patient characteristics in the West Midlands and
Northern and Yorkshire training data set, and the Eastern
Cancer Registration and Information Centre validation data set
Training
data set
(n=23 842)
External
validation
data set
(n=14 526)
Region NYCRIS 12 908 (54⋅1) 0 (0)
WMCIU 10 934 (45⋅9) 0 (0)
ECRIC 0 (0) 14 526 (100)
Age (years) 70–74 6399 (26⋅8) 3776 (26⋅0)
75–79 6325 (26⋅5) 3813 (26⋅2)
80–84 5513 (23⋅1) 3330 (22⋅9)
85–89 3661 (15⋅4) 2234 (15⋅4)
90–94 1482 (6⋅2) 1040 (7⋅2)
95–99 408 (1⋅7) 307 (2⋅1)
≥100 54 (0⋅2) 26 (0⋅2)
Deprivation
category
1 (low) 3857 (16⋅2) 2882 (19⋅8)
2 4867 (20⋅4) 3634 (25⋅0)
3 4753 (19⋅9) 4025 (27⋅7)
4 5060 (21⋅2) 2851 (19⋅6)
5 (high) 5298 (22⋅2) 1134 (7⋅8)
Missing 7 (0⋅0) 0 (0)
Detection Screened 1345 (5⋅6) 1330 (9⋅2)
Symptomatic 22 497 (94⋅4) 13 196 (90⋅8)
Values in parentheses are percentages unless indicated otherwise.
NYCRIS, Northern and Yorkshire Cancer Registry and Information Ser-
vice; WMCIU, West Midlands Cancer Intelligence Unit; ECRIC, Eastern
Cancer Registration and Information Centre.
source software package R (R Foundation for Statistical
Computing, Vienna, Austria)14.
The three co-variables in the other-cause mortality sub-
model (age, co-morbidity and frailty) were modelled using
the proportional hazards assumption. Frailty was approx-
imated by a version of the activities of daily living (ADL)
score15, represented by an integer value ranging from 0 to
5; 0 means no difficulties, and 5 means complete difficulty
in the components eat, toilet, dress, transfer, bathe and
walk. This variable was not recorded in the registry data, so
a Markov chain Monte Carlo approach was adapted from
Koissi and Högnäs16. This process inferred frailty weights,
that is the probability of being at each ADL level for each
patient, as well as model parameters that are the hazard
ratios of other-cause mortality for each level (Appendix
S1, supporting information). This estimation was carried
out using the open source WinBUGS package17 and the
R2WinBUGS interface18.
Hazards predicted by the submodels were combined and
transformed appropriately (Appendix S1, supporting infor-
mation) to derive probabilities of death by 2 and 5 years
(breast cancer-specific, other cause and all cause).
Table 3 Tumour characteristics in the West Midlands and
Northern and Yorkshire training data set, and the Eastern
Cancer Registration and Information Centre validation data set
Training
data set
(n=23 842)
External
validation
data set
(n= 14 526)
Tumour stage I 5140 (21⋅6) 3568 (24⋅6)
II 8444 (35⋅4) 5360 (36⋅9)
III 1871 (7⋅8) 1412 (9⋅7)
IV 1511 (6⋅3) 1041 (7⋅2)
Missing 6876 (28⋅8) 3145 (21⋅7)
Tumour size <10 mm 971 (4⋅1) 722 (5⋅0)
10–19 mm 4584 (19⋅2) 3153 (21⋅7)
20–49 mm 8486 (35⋅6) 5835 (40⋅2)
≥50 mm 1369 (5⋅7) 1062 (7⋅3)
Missing 8432 (35⋅4) 3754 (25⋅8)
Tumour grade I 3118 (13⋅1) 1516 (10⋅4)
II 10 479 (44⋅0) 6072 (41⋅8)
III 5746 (24⋅1) 3586 (24⋅7)
Missing 4499 (18⋅9) 3352 (23⋅1)
Node-positive No 6548 (27⋅5) 4122 (28⋅4)
Yes 5579 (23⋅4) 2807 (19⋅3)
Missing 11 715 (49⋅1) 7597 (52⋅3)
ER-positive No 5115 (21⋅5) 6525 (44⋅9)
Yes 18 727 (78⋅5) 8001 (55⋅1)
HER2-positive No 4758 (20⋅0) 4053 (27⋅9)
Yes 850 (3⋅6) 656 (4⋅5)
Missing 18 234 (76⋅5) 9817 (67⋅6)
Co-morbidity
score
0 16 686 (70⋅0) 11 964 (82⋅4)
1 1883 (7⋅9) 1451 (10⋅0)
2 979 (4⋅1) 616 (4⋅2)
≥3 550 (2⋅3) 397 (2⋅7)
Missing 3744 (15⋅7) 98 (0⋅7)
Treatment Primary endocrine
therapy
10 471 (43⋅9) 6037 (41⋅6)
Surgery 13 371 (56⋅1) 8489 (58⋅4)
Vital status Censored 7076 (29⋅7) 5520 (38⋅0)
Breast cancer
death
7312 (30⋅7) 4008 (27⋅6)
Other death 9454 (39⋅7) 4998 (34⋅4)
Mean survival
(days)
1906 1768
Values in parentheses are percentages unless indicated otherwise. ER,
oestrogen receptor; HER2, human epidermal growth factor receptor 2.
Model training data, obtained from the West Midlands
(West Midlands Cancer Intelligence Unit, WMCIU) and
the Northern and Yorkshire (Northern and Yorkshire Can-
cer Registry and Information Service, NYCRIS) cancer
registry regions, included all first diagnoses of invasive
breast cancer in women aged 70 years and over between
2002 and 2010. The patient and disease variables were
representative of wider UK national data in terms of age
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Table 4 Internal model validation: calibration and discrimination results for breast cancer and all-cause mortality at 2 and 5 years
across the whole training data set
No. of
patients
Observed
mortality
Predicted
mortality
Absolute difference,
predicted – observed (%)
Relative difference,
predicted versus observed (%) AUC
2-year BCM 16 201 1016 (6⋅3) 1022 (6⋅3) 0 0⋅5 0⋅77
5-year BCM 16 194 2556 (15⋅8) 2629 (16⋅2) 0⋅4 2⋅8 0⋅75
2-year ACM 16 201 2477 (15⋅3) 2546 (15⋅7) 0⋅4 2⋅8 0⋅79
5-year ACM 16 194 6320 (39⋅0) 6399 (39⋅5) 0⋅5 1⋅2 0⋅80
Values in parentheses are percentages. Discrimination, calculated as area under the receiver operating characteristic (ROC) curve (AUC), indicates
concordance between predicted and observed risk; a value of 0⋅5 represents no concordance and 1 represents perfect concordance. BCM, breast cancer
mortality; ACM, all-cause mortality.
distribution, deprivation pattern, tumour stage and biolog-
ical subtype distributions (Tables 2 and 3). The data from
these regions were also of the highest available quality in
terms of accuracy and completeness in comparison with
wider UK data. Survival data were derived from death
certificates from the Office for National Statistics, with
a mean follow up of 5⋅2 years and a censoring date of
17 January 2017. Details of data preprocessing have been
reported elsewhere19 and are summarized in Appendix S1
and Table S1 (supporting information). For external valida-
tion, Eastern Cancer Registration and Information Centre
(ECRIC) data were obtained on all first diagnoses of inva-
sive breast cancer in women aged 70 years or more between
2002 and 2012, with a mean follow-up of 4⋅8 years. The
majority of administrative censoring for the validation data
occurred in January 2016 (Appendix S1, supporting infor-
mation). Cancer registry data in the UK do not record
co-morbidities or frailty. Co-morbidity was derived from
linked records in the HES data set. HES records were
searched from 18 months before the date of diagnosis and
linkage was made using National Health Service (NHS)
number, date of birth, sex and postcode.
Both data sets contained variables with a non-negligible
number of missing values (Tables 2 and 3). Multiple imputa-
tion was used to create complete versions to avoid exclud-
ing patients with any missing data. Missing a variable
is often dependent on patient characteristics, leading to
potential exclusion bias. The distribution of these variables
in patients with similar characteristics was used to impute
values for the missing variables. To account for the uncer-
tainty in this process, 15 imputations of both data sets were
created. The analysis was done on each imputation, and
results combined using Rubin’s rules20. Details of the impu-
tation process have been published previously19 and are
summarized in Appendix S1 and Table S2 (supporting infor-
mation).
Validation comprised assessment of calibration and dis-
crimination. Calibration tests whether the model predicts
the correct number of deaths over a given interval. The
time points chosen for validation were 2 and 5 years, owing
to the age and typical frailty of the women who will use
the tool. For 2-year calibration, for instance, all women
with complete 2-year follow-up (excluding those lost to
follow-up before 2 years) were selected and the sum of
2-year all-cause mortality predictions was compared with
the number of observed deaths. Discrimination measures
whether patients with a higher predicted probability of
death are, on average, those who die more frequently. Dis-
crimination is calculated as the area under the receiver
operating characteristic (ROC) curve (AUC); an AUC of
0⋅5 represents the equivalent of randomly allocated mor-
tality probabilities, and an area of 1 represents perfect
concordance between probabilities and outcomes8,21. All
validation results were produced by averaging over the
individual results for the 15 imputed data sets and also by
weighted averaging of mortality predictions using the ADL
level frailty weights inferred for each patient.
Results
Patient and tumour characteristics for the training and
external data sets are shown in Tables 2 and 3. The cohorts
were similar, except for a higher proportion of screened
patients (9⋅2 versus 5⋅6 per cent) and a lower proportion
of patients in the high-deprivation group (7⋅8 versus 22⋅2
per cent) in the external versus training data sets. After pre-
processing, 18 727 (78⋅5 per cent) patients in the training
data set were classified as ER-positive; of these, 10 085
women (53⋅9 per cent) had surgery and 8642 (46⋅1 per cent)
received primary endocrine therapy.
Hazard ratios
Hazard ratios for surgery versus primary endocrine ther-
apy groups were patient-dependent. Values for a range of
subgroups are shown in Table S3 (supporting information).
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Table 5 Internal calibration check of the model: comparison of observed and predicted all-cause mortality at 2 and 5 years for
subgroups of patients
2 years 5 years
No. of
patients
Observed
mortality
Predicted
mortality
Absolute
mortality
difference
(%)*
Relative
mortality
difference
(%)†
No. of
patients
Observed
mortality
Predicted
mortality
Absolute
mortality
difference
(%)*
Relative
mortality
difference
(%)†
All patients 16 201 2477 (15⋅3) 2546 0⋅4 2⋅8 16 194 6320 (39⋅0) 6399 0⋅5 1⋅2
Treatment
Surgery 9921 712 (7⋅2) 913 2⋅0 28⋅1 9915 2274 (22⋅9) 2675 4⋅0 17⋅6
Primary endocrine
therapy
6280 1765 (28⋅1) 1633 –2⋅1 –7⋅5 6279 4046 (64⋅4) 3724 –5⋅1 –8⋅0
Age (years)
70–74 4445 284 (6⋅4) 275 –0⋅2 –3⋅4 4443 901 (20⋅3) 870 –0⋅7 –3⋅4
75–79 4391 441 (10⋅0) 463 0⋅5 5⋅2 4389 1307 (29⋅8) 1351 1⋅0 3⋅4
80–84 3703 596 (16⋅1) 632 1⋅0 6⋅1 3700 1581 (42⋅8) 1668 2⋅3 5⋅4
85–89 2413 652 (27⋅1) 655 0⋅0 0⋅2 2413 1524 (63⋅2) 1511 –0⋅5 –0⋅8
≥90 1249 504 (40⋅4) 521 1⋅4 3⋅5 1249 1007 (80⋅6) 999 –0⋅6 –0⋅8
Node-positive
No 9404 1083 (11⋅5) 1208 1⋅3 11⋅5 9402 2981 (31⋅7) 3215 2⋅5 7⋅8
Yes 6797 1394 (20⋅5) 1338 –0⋅8 –4⋅0 6792 3339 (49⋅2) 3184 –2⋅3 –4⋅6
Co-morbidity score
0 13 862 1793 (12⋅9) 1877 0⋅6 4⋅7 13 856 4883 (35⋅2) 5005 0⋅9 2⋅5
1 1560 416 (26⋅7) 377 –2⋅5 –9⋅3 1560 881 (56⋅5) 835 –3⋅0 –5⋅3
2 465 137 (29⋅5) 147 2⋅2 7⋅6 465 316 (68⋅0) 304 –2⋅7 –3⋅9
≥3 314 131 (41⋅7) 145 4⋅5 10⋅9 313 240 (76⋅7) 255 4⋅5 6⋅0
Detection
Screen-detected 1110 28 (2⋅5) 44 1⋅4 53⋅9 1110 88 (7⋅9) 147 5⋅3 66⋅3
Symptomatic 15 091 2449 (16⋅2) 2502 0⋅4 2⋅2 15 084 6232 (41⋅3) 6252 0⋅1 0⋅3
Tumour grade
I 3137 414 (13⋅2) 437 0⋅7 5⋅5 3137 1067 (34⋅0) 1106 1⋅2 3⋅6
II 9596 1417 (14⋅8) 1491 0⋅8 5⋅2 9592 3671 (38⋅3) 3753 0⋅9 2⋅2
III 3468 646 (18⋅6) 618 –0⋅8 –4⋅3 3465 1582 (45⋅7) 1540 –1⋅2 –2⋅6
Tumour size (mm)
<10 977 78 (8⋅0) 92 1⋅4 18⋅4 976 217 (22⋅2) 256 4⋅1 18⋅4
10–19 4874 509 (10⋅4) 576 1⋅4 13⋅2 4873 1365 (28⋅0) 1555 3⋅9 13⋅9
20–29 5128 734 (14⋅3) 799 1⋅2 8⋅8 5126 1975 (38⋅5) 2024 0⋅9 2⋅5
30–49 3689 720 (19⋅5) 694 –0⋅7 –3⋅5 3687 1807 (49⋅0) 1690 –3⋅2 –6⋅5
≥50 1533 436 (28⋅4) 385 –3⋅3 –11⋅7 1532 956 (62⋅4) 874 –5⋅3 –8⋅6
Deprivation category
Low 2673 313 (11⋅7) 365 2⋅0 16⋅7 2672 867 (32⋅4) 947 3⋅0 9⋅3
Medium 9971 1538 (15⋅4) 1578 0⋅4 2⋅6 9966 3855 (38⋅7) 3952 1⋅0 2⋅5
High 3557 626 (17⋅6) 603 –0⋅7 –3⋅7 3556 1598 (44⋅9) 1500 –2⋅7 –6⋅1
Values in parentheses are percentages. *Predicted – observed; †predicted versus observed.
Internal validation
Overall calibration of the model was good (Table 4). At
2 and 5 years, predicted breast cancer and other-cause
mortality differed from observed rates by less than 1
per cent in all instances. At 5 years, there was a slight
overprediction of breast cancer mortality (2629 pre-
dicted versus 2556 observed deaths; P = 0⋅142) and
all-cause mortality (6399 versus 6320; P = 0⋅583). The
AUC representing discrimination was 0⋅75 or above
for all mortality measures (Table 4). Performance was
similar to that of PREDICT (AUC 0⋅76–0⋅78)8. Fig. S1
(supporting information) shows predicted and observed
5-year all-cause mortality by deciles of observed mortality.
Calibration was good for the intermediate deciles, but
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Fig. 1 External calibration plot of 5-year all-cause mortality
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Patients are divided into ten groups using deciles of mortality predictions.
For each group, the average 5-year all-cause mortality prediction is plotted
against the average observed mortality. A straight line of unit gradient
represents perfect calibration.
less good for low-risk (overprediction) and moderately
high-risk (under-prediction) deciles.
The degree of underestimation or overestimation of
all-cause mortality varied between subgroups (Table 5). The
5-year relative mortality difference exceeded +/– 10 per
cent for the surgery subgroup, the screened population
subgroup and two of the tumour size subgroups (less
than 10 mm and 10–19 mm). The 2-year relative mortal-
ity difference exceeded +/–10 per cent for the surgery,
node-negative, co-morbidity score ≥ 3 and screen-detected
subgroups. All-cause mortality was also overpredicted for
patients with smaller tumours and underpredicted for those
with the largest tumours (over 50 mm). At both 2 and
5 years, mortality was overpredicted in the surgery sub-
group and underpredicted in the primary endocrine ther-
apy subgroup. These subgroup differences were driven by
the other-cause mortality estimates (Table S4, supporting
information), with 13⋅4 and 17⋅3 per cent underprediction
for patients who had primary endocrine therapy at 2 and
5 years respectively.
External validation
Overall calibration was also good in the external data set
(Table S5, supporting information). Five-year predicted
breast cancer mortality exceeded the observed rate in
the training data by 0⋅5 per cent, and the difference for
all-cause mortality was 0⋅1 per cent. Two-year predicted
all-cause mortality exceeded the observed rate by 1⋅2 per
cent, whereas at 5 years there was a small underprediction
(–0⋅9 per cent). Fig. 1 shows predicted and observed 5-year
all-cause mortality by deciles of observed mortality. Cali-
bration was good for the higher-risk deciles, but there was
some overprediction for the low-risk deciles. Discrimina-
tion results for 2- and 5-year breast cancer mortality and
all-cause mortality in the external validation data set had
AUC values in the range 0⋅75–0⋅80 (Table S5, supporting
information). The results of external subgroup validation
are shown in Table S6 (supporting information).
Discussion
A prognostic model for women aged 70 years or older with
ER-positive early breast cancer was developed and val-
idated. This model was targeted specifically at support-
ing the decision of whether to undergo surgery or opt
for primary endocrine therapy. The model was developed
using a large cohort of patients from the West Midlands
(WMCIU) and the Northern and Yorkshire (NYCRIS)
cancer registries. These together cover around 25 per cent
of the population in England, and are regarded as being
broadly representative of the UK demographic distribu-
tion. The model was validated using data from the East-
ern Cancer Registry (ECRIC) in England. The model was
shown to be well calibrated for all-cause mortality and
to have good discrimination, with similar performance to
other prognostic models in early breast cancer, such as
PREDICT. The model additionally performed well on
the external validation data set. The Age Gap prognostic
model provides outputs for both breast cancer mortality
and other-cause mortality. This is an important issue in
older patients, who have an increased risk of dying from
other causes. By age 85 years, around three-quarters of
deaths are from causes other than breast cancer.
The findings of this analysis are not directly compara-
ble to those of other predictive models in breast cancer.
PREDICT and other commonly used models focus on
decisions around adjuvant therapy following breast cancer
surgery, rather than whether or not a patient will bene-
fit from surgery itself. These models are typically trained
on a mixed-age population, and not designed to deal with
the greater other-cause mortality rates among patients aged
70 years or more. In contrast, the Age Gap model is tar-
geted at older women for whom the benefits versus harms
of surgery are more complex, owing to co-morbidities and
frailty.
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Bridging the Age Gap
In this model, other-cause mortality is underpredicted
for patients treated with primary endocrine therapy (abso-
lute mortality difference –6⋅8 per cent) (Table S4, sup-
porting information). The other-cause mortality model
has taken the first step to incorporating the impact of
co-morbidities and frailty on individual-patient predictions
of mortality, but the prediction is currently subject to lim-
itations. Cancer registry data in the UK do not record
co-morbidities or frailty. Here, co-morbidity was derived
from linked records in the HES data set. Data were avail-
able from HES only if a patient had a hospital inpatient
or day-case admission preceding their cancer diagnosis.
This methodology relies heavily on the accuracy of cod-
ing within HES. HES data are likely to under-record
co-morbidities in patients who have chronic co-morbidities
managed in the community or outpatient setting, such as
diabetes or dementia. On average, women are more likely
to receive primary endocrine therapy if they are older
and have chronic co-morbidities22,23. Under-reporting of
co-morbidities in patients undergoing primary endocrine
therapy may, at least in part, contribute to the underpre-
diction of the other-cause mortality for such patients.
Validation of the model was conducted at 2 and 5 years
after diagnosis as sufficient 10-year uncensored follow-up
data were not available. This also reflects the decision
that these prognostic timescales are the most appropriate
for the majority of women in this older age group, for
many of whom a 10-year prediction may not give a posi-
tive message. Further validation will be carried out when
full data are available, and presentation of 10-year pre-
dictions will be reviewed in the light of user and patient
input.
No measure of frailty is included in cancer registry data
sets. Frailty was approximated by a version of the ADL
score as used by Stineman and colleagues15. Values from
this US study were used to form priors for the parame-
ters in the developed model. The mean age of participants,
77⋅4 years, was similar to that in the UK population. How-
ever, the distributions of ADL level in these study partic-
ipants may not fully reflect the UK population of older
women with breast cancer. Further validation of the cur-
rent methodology will be possible using data collected in
the prospective Bridging the Age Gap cohort study, which
includes co-morbidities and frailty data, once sufficiently
mature survival data become available.
The present analysis benefits from the large retrospective
data set of patients with breast cancer. This reduces the
biases from exclusion criteria of many RCTs, which often
include both older age and complex co-morbidity. Use
of routinely collected data, however, resulted in a high
proportion of missing values, especially for patients in the
non-surgical group. For instance, tumour size and clinical
node status based on imaging was not clearly recorded in
these patients. No perfect method exists for obtaining these
missing data. Multiple imputation, however, is less prone to
bias than complete-case analysis and/or treating ‘missing’
as a category. It also allows the propagation of uncertainty
owing to missing data into the estimates of co-variable
effects.
The prognostic model is part of a decision support inter-
vention (DESI) including an online tool (https://agegap
.shef.ac.uk/) with two other patient-facing decision aids24,
tailored to the information needs and preferences of older
women25,26 in decision-making between surgery and pri-
mary endocrine therapy. This DESI has been developed
for women whose choice between surgery and primary
endocrine therapy is not clear cut. The online tool predic-
tions are generated by the model described in the present
study. The co-morbidity score is determined by entering
a history of patient co-morbidities via a tick-box list. The
frailty score is similarly generated by entering the level of
difficulty experience in six functional domains. In the cur-
rent version, for reasons of patient sensitivity, the depriva-
tion level is not entered and a medium level is assumed for
all patients. The other model inputs are straightforward.
A prospective cohort study, part of the Bridging the Age
Gap in Breast Cancer project, will finally offer a more
detailed data set to further assess the effects of surgery and
primary endocrine therapy on survival in older women.
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